News & Updates

Select men who underwent radical prostatectomy (RP) for organ-confined prostate cancer may safely use testosterone therapy, which does not seem to cause biochemical recurrence (BCR), according to a study.

The glucose-lowering drug metformin appears to be associated with fewer asthma attacks, with further reductions when metformin is used in combination with GLP-1RAs, according to a study.

Patients with inflammatory bowel disease (IBD) who achieve a normal C-reactive protein (CRP) and endoscopic healing exhibit significantly higher ustekinumab trough levels, reveals a study. A cutoff level of 4.8 µg/mL predicts CRP normalization.

Monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) or its receptor do not appear to contribute to heightened risk of cardiovascular disease (CVD) relative to onabotulinumtoxinA in adults with migraine at high CVD risk, according to a study.

Chemotherapy combined with blinatumomab (blin) delivers significant improvements in disease-free survival (DFS) in children with newly diagnosed National Cancer Institute standard risk (SR) B-cell acute lymphoblastic leukaemia (B-ALL), according to the results of the AALL1731 study presented at ASH 2024.

The addition of tafasitamab (tafa) to lenalidomide and rituximab (len+R) significantly improves progression-free survival (PFS) in patients with relapsed or refractory (R/R) follicular lymphoma (FL), as shown in a phase III study presented at ASH 2024. The safety profile of this combination is manageable and consistent with expected toxicities.

Treatment with belzutifan improves progression-free survival (PFS) and objective response rate (ORR) in East Asian patients with advanced clear-cell renal cell carcinoma (RCC) compared with everolimus, according to the updated subgroup data of the phase III LITESPARK-005 trial presented at ESMO Asia 2024.